

Thoracoscopic surgical ablation versus catheter ablation as first-line treatment for long-standing persistent atrial fibrillation: the CASA-AF RCT

Shouvik Haldar,^{1†} Habib R Khan,^{2†} Vennela Boyalla,¹
Ines Kralj-Hans,¹ Simon Jones,³ Joanne Lord,⁴
Oluchukwu Onyimadu,⁵ Anitha Sathishkumar,⁶
Toufan Bahrami,¹ Jonathan Clague,¹ Anthony De Souza,¹
Darrel Francis,⁷ Wajid Hussain,¹ Julian Jarman,¹
David G Jones,¹ Zhong Chen,¹ Neeraj Mediratta,⁸
Jonathan Hyde,⁹ Michael Lewis,⁹ Raad Mohiaddin,¹
Tushar Salukhe,¹ Caroline Murphy,¹⁰ Joanna Kelly,¹⁰
Rajdeep Khattar,¹ William D Toff,¹¹ Vias Markides,¹
James McCready,⁹ Dhiraj Gupta⁸ and Tom Wong^{1*}
on behalf of the CASA-AF Investigators

¹Cardiology Department, Royal Brompton and Harefield NHS Foundation Trust, London, UK

²London Health Sciences Centre, University of Western Ontario, London, ON, Canada

³Centre for Healthcare Innovation and Delivery Science, Department of Population Health, New York University Grossman School of Medicine, New York, NY, USA

⁴Wessex Institute, University of Southampton, Southampton, UK

⁵Nuffield Department of Primary Care Health Sciences, Medical Sciences Division, University of Oxford, Oxford, UK

⁶Invasive Cardiac Physiology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

⁷National Heart and Lung Institute, Imperial College London, London, UK

⁸Cardiology Department, Liverpool Heart and Chest Hospital, Liverpool, UK

⁹Cardiology Department, Brighton and Sussex University Hospital NHS Trust, Brighton, UK

¹⁰King's Clinical Trials Unit at King's Health Partners, King's College London, Institute of Psychiatry, London, UK

¹¹Department of Cardiovascular Sciences, University of Leicester and National Institute for Health Research Leicester Biomedical Research Centre, Glenfield Hospital, Leicester, UK

*Corresponding author tom.wong@imperial.ac.uk

†Joint first authors

Declared competing interests of authors: Joanne Lord is a member of the Health Technology National Stakeholder Advisory Group (2015–20). James McCready reports personal fees from Medtronic plc (Dublin, Ireland) and non-financial support from Biosense Webster Inc. (Irvine, CA, USA) outside the submitted work. Dhiraj Gupta reports grants and personal fees from Biosense Webster Inc. during the conduct of the study. Vias Markides reports grants and personal fees from Biosense Webster Inc. outside the submitted work.

Published October 2021

DOI: 10.3310/eme08180

Plain English summary

The CASA-AF RCT

Efficacy and Mechanism Evaluation 2021; Vol. 8: No. 18

DOI: 10.3310/eme08180

NIHR Journals Library www.journalslibrary.nihr.ac.uk

Plain English summary

Atrial fibrillation is a complex heart condition that can lead to stroke and heart failure and affects patients' quality of life. Common symptoms are palpitations, tiredness, breathlessness and dizziness.

Patients can have occasional (paroxysmal) episodes of fibrillation that stop within 1 week. Other patients have fibrillation lasting > 1 week (persistent), and some are in continuous fibrillation for > 1 year (long-standing persistent).

Heart rate and rhythm can be corrected with medications and electrical shock therapy (cardioversion), but these treatments are often not satisfactory either because of their side effects or because they are simply not effective. Catheter ablation is a standard-care treatment for symptomatic fibrillation, but some patients need more than one procedure to restore normal heart rhythm.

Keyhole surgical ablation is a newer treatment, and some studies report much greater success with this than with catheter ablation. In this study, we recruited 120 patients with long-standing persistent atrial fibrillation and treated half of them with catheter ablation and the other half with surgical ablation. A small heart rhythm monitoring device, inserted under the skin, collected heart rhythm data following ablation.

Both treatments restored normal heart rhythm in just one-third of patients. Atrial fibrillation returned within 1 year to patients in both groups; however, in over 70% of patients, these episodes were occasional and of shorter duration. Serious complications within 30 days of the procedure occurred in 10 out of 55 patients in the surgical ablation group, compared with 6 out of 60 patients in the catheter ablation group. However, one patient died following surgical ablation and we observed a greater number of late complications in this group.

Patients reported reduced symptoms and better quality of life over the 12 months' follow-up, but those randomised to catheter ablation had larger improvements. Surgical ablation often requires admission to a high-dependency unit after the procedure, is associated with longer hospital stays and more complications during follow-up, and costs more than catheter ablation.

Efficacy and Mechanism Evaluation

ISSN 2050-4365 (Print)

ISSN 2050-4373 (Online)

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

Editorial contact: journals.library@nihr.ac.uk

The full EME archive is freely available to view online at www.journalslibrary.nihr.ac.uk/eme. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk

Criteria for inclusion in the *Efficacy and Mechanism Evaluation* journal

Reports are published in *Efficacy and Mechanism Evaluation* (EME) if (1) they have resulted from work for the EME programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

EME programme

The Efficacy and Mechanism Evaluation (EME) programme funds ambitious studies evaluating interventions that have the potential to make a step-change in the promotion of health, treatment of disease and improvement of rehabilitation or long-term care. Within these studies, EME supports research to improve the understanding of the mechanisms of both diseases and treatments.

The programme supports translational research into a wide range of new or repurposed interventions. These may include diagnostic or prognostic tests and decision-making tools, therapeutics or psychological treatments, medical devices, and public health initiatives delivered in the NHS.

The EME programme supports clinical trials and studies with other robust designs, which test the efficacy of interventions, and which may use clinical or well-validated surrogate outcomes. It only supports studies in man and where there is adequate proof of concept. The programme encourages hypothesis-driven mechanistic studies, integrated within the efficacy study, that explore the mechanisms of action of the intervention or the disease, the cause of differing responses, or improve the understanding of adverse effects. It funds similar mechanistic studies linked to studies funded by any NIHR programme.

The EME programme is funded by the Medical Research Council (MRC) and the National Institute for Health Research (NIHR), with contributions from the Chief Scientist Office (CSO) in Scotland and National Institute for Social Care and Health Research (NISCHR) in Wales and the Health and Social Care Research and Development (HSC R&D), Public Health Agency in Northern Ireland.

This report

The research reported in this issue of the journal was funded by the EME programme as project number 12/127/127. The contractual start date was in January 2015. The final report began editorial review in June 2020 and was accepted for publication in December 2020. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The EME editors and production house have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research. The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, the MRC, NETSCC, the EME programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the EME programme or the Department of Health and Social Care.

© Queen's Printer and Controller of HMSO 2021. This work was produced by Haldar *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).

NIHR Journals Library Editor-in-Chief

Professor Ken Stein Professor of Public Health, University of Exeter Medical School, UK

NIHR Journals Library Editors

Professor John Powell Chair of HTA and EME Editorial Board and Editor-in-Chief of HTA and EME journals. Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK, and Professor of Digital Health Care, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK

Professor Andrée Le May Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals) and Editor-in-Chief of HS&DR, PGfAR, PHR journals

Professor Matthias Beck Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

Dr Tessa Crilly Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin Senior Scientific Advisor, Wessex Institute, UK

Dr Peter Davidson Consultant Advisor, Wessex Institute, University of Southampton, UK

Ms Tara Lamont Senior Scientific Adviser (Evidence Use), Wessex Institute, University of Southampton, UK

Dr Catriona McDaid Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

Professor William McGuire Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads Emeritus Professor of Wellbeing Research, University of Winchester, UK

Professor James Raftery Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts Professor of Child Health Research, UCL Great Ormond Street Institute of Child Health, UK

Professor Jonathan Ross Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Ken Stein Professor of Public Health, University of Exeter Medical School, UK

Professor Jim Thornton Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Please visit the website for a list of editors: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: journals.library@nihr.ac.uk